Other work indicates that decitabine can enhance CD36-mediated immunosuppression in leukemia cells, leading to chemotherapy resistance, whereas statins may improve decitabine efficacy by reducing lipoproteins transported via CD36 and thereby alleviating immunosuppression [18]. Here, CD36 is linked to leukemia.